- Daiichi Sankyo Co Ltd DSNKY said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason.
- However, the Nikkei newspaper reported that there were safety concerns.
- In March, the company started a Phase 1 trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients.
- Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
- Price Action: DSNKY closed at $23.76 on Monday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.